Advertisement

Target Organ Damage and RAAS Blockade

Chapter
  • 1.1k Downloads
Part of the Current Cardiovascular Therapy book series (CCT, volume 5)

Abstract

This chapter will focus on the influence of target organ damage, particularly of left ventricular hypertrophy and subclinical kidney dysfunction, in the choice of ACEIs or ARBs therapy in patients with hypertension and heart failure.

Keywords

ACEIs ARBs RAAS DRIs RAAS blockade Dual therapy Monotherapy Organ damage Homeostasis 

References

  1. 1.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.CrossRefGoogle Scholar
  2. 2.
    Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007;72:879–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Balakumar P, Jagadeesh G. Cardiovascular and renal pathologic implications of prorenin, renin, and the (pro)renin receptor: promising young players from the old renin-angiotensin-aldosterone system. J Cardiovasc Pharmacol. 2010;56:570–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Bangalore S, Kumar S, Wetterslev J, et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011;342:d2234.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Bidani AK, Griffin KA, Epstein M. Hypertension and chronic kidney disease progression: why the suboptimal outcomes? Am J Med. 2012;125:1057–62.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.PubMedCrossRefGoogle Scholar
  8. 8.
    Cowan BR, Young AA. Left ventricular hypertrophy and renin-angiotensin system blockade. Curr Hypertens Rep. 2009;11:167–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.PubMedCrossRefGoogle Scholar
  10. 10.
    Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Dusing R, Sellers F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin. 2009;25:2287–301.PubMedCrossRefGoogle Scholar
  12. 12.
    Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Fernandez Juarez G, Luno J, Barrio V, et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis. 2013;61:211–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Ferrari R, Boersma E. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. Expert Rev Cardiovasc Ther. 2013;11:705–17.PubMedCrossRefGoogle Scholar
  15. 15.
    Ferrari R, Rosano GM. Not just numbers, but years of science: putting the ACE inhibitor-ARB meta-analyses into context. Int J Cardiol. 2013;166(2):286–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892–903.PubMedCrossRefGoogle Scholar
  18. 18.
    Gosse P. Left ventricular hypertrophy – the problem and possible solutions. J Int Med Res. 2005;33 Suppl 1:3A–11.PubMedCrossRefGoogle Scholar
  19. 19.
    Grandi AM, Maresca AM. Blockade of the renin-angiotensin-aldosterone system: effects on hypertensive target organ damage. Cardiovasc Hematol Agents Med Chem. 2006;4:219–28.PubMedCrossRefGoogle Scholar
  20. 20.
    Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Hayashi T, Takai S, Yamashita C. Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus. Curr Vasc Pharmacol. 2010;8:189–97.PubMedCrossRefGoogle Scholar
  22. 22.
    Houston Miller N. Cardiovascular risk reduction with renin-angiotensin aldosterone system blockade. Nurs Res Pract. 2010;2010:101749.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16:80–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Lam CS, Carson PE, Anand IS, et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012;5:571–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–62.PubMedCrossRefGoogle Scholar
  28. 28.
    Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–86.PubMedCrossRefGoogle Scholar
  29. 29.
    Luft FC. Perspective on combination RAS blocking therapy: Off-TARGET, Dis-CORD, MAP-to-nowhere, low ALTITUDE, and NEPHRON-D. Am J Nephrol. 2014;39:46–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.PubMedCrossRefGoogle Scholar
  31. 31.
    Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–67.PubMedCrossRefGoogle Scholar
  32. 32.
    McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767–71.PubMedCrossRefGoogle Scholar
  33. 33.
    Menard J, Campbell DJ, Azizi M, et al. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation. 1997;96:3072–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440–4.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13.PubMedCrossRefGoogle Scholar
  36. 36.
    Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Pende A, Dallegri F. Renin-angiotensin antagonists: therapeutic effects beyond blood pressure control? Curr Pharm Des. 2012;18:1011–20.PubMedCrossRefGoogle Scholar
  38. 38.
    Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–77.PubMedCrossRefGoogle Scholar
  39. 39.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.PubMedCrossRefGoogle Scholar
  40. 40.
    Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–66.PubMedCrossRefGoogle Scholar
  41. 41.
    Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–52.PubMedCrossRefGoogle Scholar
  42. 42.
    Ruggenenti P, Fassi A, Ilieva A, et al. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens. 2011;29:207–16.PubMedCrossRefGoogle Scholar
  43. 43.
    Ruilope LM, Jakobsen A, Heroys J, et al. Prospects for renovascular protection by more aggressive renin-angiotensin system control. Medscape J Med. 2008;10(Suppl):S5.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Rutherford JD, Pfeffer MA, Moyè LA, et al. Effect of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. SAVE Investigators. Cirulation. 1994;90:1731–8.Google Scholar
  45. 45.
    Sanders GD, Coeytaux R, Dolor RJ, et al. Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011.Google Scholar
  46. 46.
    Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013;61:131–42.PubMedCrossRefGoogle Scholar
  47. 47.
    Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30:1351–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208–19.PubMedCrossRefGoogle Scholar
  49. 49.
    Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218–26.PubMedCrossRefGoogle Scholar
  50. 50.
    Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114:838–54.PubMedCrossRefGoogle Scholar
  51. 51.
    Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678–84.PubMedCrossRefGoogle Scholar
  52. 52.
    The AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–8.Google Scholar
  53. 53.
    The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35.CrossRefGoogle Scholar
  54. 54.
    The Editors of the Lancet. Retraction – Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2009;374:1226.CrossRefGoogle Scholar
  55. 55.
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.CrossRefGoogle Scholar
  56. 56.
    Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25:951–8.PubMedCrossRefGoogle Scholar
  57. 57.
    van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33:2088–97.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Verdecchia P, Gentile G, Angeli F, et al. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Ther Adv Cardiovasc Dis. 2012;6:81–91.PubMedCrossRefGoogle Scholar
  59. 59.
    Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VSI. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther. 2007;29:1803–24.PubMedCrossRefGoogle Scholar
  61. 61.
    Wong J. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed. Diab Vasc Dis Res. 2013;10:193–201.PubMedCrossRefGoogle Scholar
  62. 62.
    Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81.PubMedCrossRefGoogle Scholar
  63. 63.
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.PubMedCrossRefGoogle Scholar
  64. 64.
    Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of Medical Sciences, Centre for Clinical and Basic ResearchIRCCS San Raffaele PisanaRomeItaly
  2. 2.Laboratory of Vascular PhysiologyIRCCS San RaffaeleLondonUK
  3. 3.Cardiovascular and Cell Science InstituteSt Georges UniversityLondonUK

Personalised recommendations